195 related articles for article (PubMed ID: 23884447)
1. Correlation of breast cancer axillary lymph node metastases with stem cell mutations.
Donovan CA; Pommier RF; Schillace R; O'Neill S; Muller P; Alabran JL; Hansen JE; Murphy JA; Naik AM; Vetto JT; Pommier SJ
JAMA Surg; 2013 Sep; 148(9):873-8. PubMed ID: 23884447
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
Flatley E; Ang D; Warrick A; Beadling C; Corless CL; Troxell ML
Hum Pathol; 2013 Jul; 44(7):1320-7. PubMed ID: 23352210
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer: Mutations in breast cancer stem cells correlate with metastases.
Marchesi V
Nat Rev Clin Oncol; 2013 Oct; 10(10):546. PubMed ID: 23939549
[No Abstract] [Full Text] [Related]
4. Breast cancer stem cells--ready for their close-up?
Calhoun KE
JAMA Surg; 2013 Sep; 148(9):878. PubMed ID: 23884369
[No Abstract] [Full Text] [Related]
5. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
6. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Dunlap J; Le C; Shukla A; Patterson J; Presnell A; Heinrich MC; Corless CL; Troxell ML
Breast Cancer Res Treat; 2010 Apr; 120(2):409-18. PubMed ID: 19418217
[TBL] [Abstract][Full Text] [Related]
7. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
Kehr EL; Jorns JM; Ang D; Warrick A; Neff T; Degnin M; Lewis R; Beadling C; Corless CL; Troxell ML
Hum Pathol; 2012 Dec; 43(12):2207-12. PubMed ID: 22705004
[TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients.
Tong L; Yang XX; Liu MF; Yao GY; Dong JY; Ye CS; Li M
Asian Pac J Cancer Prev; 2012; 13(11):5599-603. PubMed ID: 23317280
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
10. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
11. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma.
Barth A; Craig PH; Silverstein MJ
Cancer; 1997 May; 79(10):1918-22. PubMed ID: 9149018
[TBL] [Abstract][Full Text] [Related]
12. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria.
Harlé A; Lion M; Lozano N; Husson M; Harter V; Genin P; Merlin JL
Oncol Rep; 2013 Mar; 29(3):1043-52. PubMed ID: 23314198
[TBL] [Abstract][Full Text] [Related]
13. Tumor and breast volume ratio as a predictive factor for axillary lymph node metastases in T1c ductal invasive breast cancer: prospective observational clinico-pathological study.
Martić K; Vlajčić Z; Rudman F; Lambaša S; Tomasović-Lončarić Č; Stanec Z
Jpn J Clin Oncol; 2011 Dec; 41(12):1322-6. PubMed ID: 22039579
[TBL] [Abstract][Full Text] [Related]
14. Can we identify the group of small invasive (T1a,b) breast cancers with minimal risk of axillary lymph node involvement? A pathohistological and DNA flow cytometric study.
Bezić J; Samija-Projić I; Projić P; Ljubković J; Capkun V; Tomić S
Pathol Res Pract; 2011 Jul; 207(7):438-42. PubMed ID: 21689895
[TBL] [Abstract][Full Text] [Related]
15. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection.
Tvedskov TF
Dan Med J; 2012 Jul; 59(7):B4475. PubMed ID: 22759850
[TBL] [Abstract][Full Text] [Related]
16. [Axillary skip metastases in breast cancer].
Sun JY; Ning LS
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):352-5. PubMed ID: 18953834
[TBL] [Abstract][Full Text] [Related]
17. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
[TBL] [Abstract][Full Text] [Related]
18. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
19. Preoperative axillary ultrasound and fine-needle aspiration biopsy in the diagnosis of axillary metastases in patients with breast cancer: predictors of accuracy and future implications.
Cools-Lartigue J; Sinclair A; Trabulsi N; Meguerditchian A; Mesurolle B; Fuhrer R; Meterissian S
Ann Surg Oncol; 2013 Mar; 20(3):819-27. PubMed ID: 22972506
[TBL] [Abstract][Full Text] [Related]
20. [Proliferation index and its prognostic value in invasive ductal breast carcinoma].
Falco M
Ann Acad Med Stetin; 2009; 55(1):22-30. PubMed ID: 20349588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]